Phase 2 Ovarian Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• You have agreed to take part and signed a consent form.
• You are 18 years of age or older.
• You have been diagnosed with ovarian, fallopian tube, or peritoneal cancer (or abdominal cancer that appears to have started in one of these areas).
• Your cancer type is specifically high grade serous carcinoma, endometrioid carcinoma, or clear cell carcinoma (your doctor can confirm which type you have).
• Your cancer is at an advanced stage (stage III or IV).
• You are planned to receive platinum-based chemotherapy.
• You are not pregnant at the start of chemotherapy (confirmed by your menstrual history or a urine pregnancy test if needed).
• If you are able to become pregnant, you are willing to use an effective form of contraception during the study.
• You are reasonably well and able to carry out daily activities, with a general health score of 0–2 on the WHO scale (confirm with trial site).
• You weigh between 50 and 150 kg.
• Your blood level of a marker called CA-125 was 250 kIE/L or higher when you were diagnosed.

Who may not be able to join:

• You are currently taking blood-thinning medications such as heparin, low molecular weight heparin, warfarin, or certain newer oral anticoagulants.
• You have taken heparin, low molecular weight heparin, or certain newer oral anticoagulants at any point in the past year.
• You have a known or suspected allergy to any product used in this study.
• You are currently pregnant, breastfeeding, or planning to become pregnant.
• Your cancer was first found during a Caesarean section.
• You have had abdominal surgery or another major operation within the past year.
• You have difficulty understanding or engaging with the study due to mental health, language, or other barriers.
• You have another condition or are receiving another treatment that the trial doctor believes could affect the study results (confirm with trial site).
• You have cancer that has spread to the brain.
• You are currently taking part in, or have taken part in, another clinical trial within the last 30 days.
• You are currently being treated for a blood clot condition (such as deep vein thrombosis or pulmonary embolism).
• You have had a blood clot condition within the past year.
• You have a known allergy to tinzaparin (the study drug) or any of its ingredients.
• You have experienced serious bleeding, or have a condition that puts you at high risk of serious bleeding (confirm with trial site).
• You have a severe disorder affecting your blood's ability to clot.
• You currently have or recently had a stomach or duodenal ulcer.
• You have a serious heart infection called septic endocarditis.
• You have previously had a reaction called heparin-induced thrombocytopenia (a drop in platelets caused by heparin).
• Your kidney function is significantly reduced (eGFR below 30 ml/min, tested within 14 days before starting the study drug).
• Your platelet count (cells that help blood clot) is too low (below 100 x10⁹/L, tested within 14 days before starting the study drug).
• You have been treated for another cancer within the past year (except a common type of skin cancer called basal cell carcinoma).

Important: Always verify eligibility with the trial site directly before applying.